SLNO Q3 2024 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$80M

Net Income

-$77M

EPS (Diluted)

$-1.83

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$57M

Balance Sheet

Total Assets

$297M

Total Liabilities

$32M

Stockholders' Equity

$265M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$80M	-$10M	-672.6%
Net Income	-$77M	-$11M	-605.4%